AK117 + paclitaxel

**AK117 + paclitaxel** is an experimental combination regimen under clinical investigation primarily for the treatment of advanced cancers (notably metastatic pancreatic cancer). **AK117** is a monoclonal antibody targeting CD47, an immune checkpoint protein often overexpressed on cancer cells that inhibits phagocytosis by binding to SIRPα on macrophages; by blocking this interaction, AK117 promotes anti-tumor immunity. **Paclitaxel** is a well-established chemotherapeutic agent that stabilizes microtubules and inhibits their depolymerization, thereby disrupting mitosis and promoting apoptosis in dividing cells. The combination aims to synergize cytotoxic tumor cell killing by paclitaxel with immune-mediated clearance mediated by AK117’s checkpoint inhibition.

Other names

AK117AK-117AK 117paclitaxelTaxol